| Zhou, Min |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT06697886: A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold |
|
|
| Recruiting | 3 | 480 | RoW | Antiwei Granules, Antiwei Granules Placebo | Tasly Pharmaceutical Group Co., Ltd | Common Cold | 06/25 | 07/25 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS |
|
|
| Recruiting | 2 | 55 | RoW | Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone | The First Affiliated Hospital with Nanjing Medical University | EBV-Positive DLBCL, Nos | 12/23 | 12/23 | | |
NCT05251090: A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection |
|
|
| Completed | 1 | 13 | RoW | ADVATE, FRSW107, Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection | Jiangsu Gensciences lnc. | Hemophilia A | 11/21 | 05/22 | | |
NCT06174597: Umbilical Cord Artery-derived Perivascular Stem Cells for the Critical Limb Ischemia Therapy |
|
|
| Recruiting | 1 | 40 | RoW | UCA-PSCs/bFGF or bFGF Intramuscular injection | Nanjing University | Critical Limb Ischemia | 06/24 | 06/26 | | |
SURF, NCT06539689: A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries |
|
|
| Recruiting | N/A | 240 | RoW | Sperstent® peripheral spot stent system, Everflex® self-expanding peripheral stent system | FrontAce Scientific Co., Ltd | Peripheral Arterial Disease, Stenosis, Dissection | 12/26 | 12/26 | | |
| Xia, Haiming |
NCT06571214: Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment |
|
|
| Not yet recruiting | 4 | 300 | RoW | Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®), Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®) | Nanjing University | Infertility | 12/26 | 01/27 | | |
NCT06174597: Umbilical Cord Artery-derived Perivascular Stem Cells for the Critical Limb Ischemia Therapy |
|
|
| Recruiting | 1 | 40 | RoW | UCA-PSCs/bFGF or bFGF Intramuscular injection | Nanjing University | Critical Limb Ischemia | 06/24 | 06/26 | | |
